This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
Responding to unmet needs for metastatic castration-resistant prostate cancer


Read time: 70 mins
Last updated:10th Mar 2023
Published:15th Feb 2023

Within 10 years of diagnosis, many individuals with prostate cancer develop castration-resistant prostate cancer (CRPC), which can advance to metastatic CRPC (mCRPC)1-9. Historically, mean overall survival for mCRPC is approximately 16–18 months10. The disease has no cure.

Unmet needs in metastatic castration-resistant prostate cancer include no curative treatment, and insufficient understanding of treatment selection, sequencing, or intensification, among others11-16.

This Learning Zone, spanning twelve pages on Medthority, describes current unmet needs in management of mCRPC, and outlines potential ways healthcare professionals (HCP) could meet them, with a focus on first-line mono- or combination treatments.

A range of short, informative videos, presented by experts in metastatic castration-resistant prostate cancer, complement the written content. Meet the expert oncologists below.

Meet the Experts

Allan Muir.pngAxel Merseburger

Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig-Holstein, Campus Lübeck, Germany. His research includes molecular and clinical aspects of uro-oncology. He has authored more than 300 peer-reviewed articles, and he is the principal investigator in Phase 2 and 3 clinical trials within urologic oncology.

In the video below, watch Merseburger introduce himself.

Karim Fizazi.pngKarim Fizazi

Karim Fizazi is a medical oncologist at the Institut Gustave Roussy, and Professor in Oncology at the Université Paris-Saclay, France. In an international clinical trial published in 2010, he showed that denosumab prevented complications of bony metastases from prostate cancer. In the 2015 GETUG-12 trial, he established that early chemotherapy prevented relapse in men with localised prostate cancer at high risk for relapse. He has published more than 400 peer-reviewed articles.

Watch Fizazi introduce himself in the video below.


  1. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN guidelines insights: prostate cancer, version 1.2021. J NCCN. 2021;19(2):134–143.
  2. Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. 2020;31:1119–1134.
  3. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J NCCN. 2019;17(5):479–505.
  4. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Euro Urol. 2017;71(4):618–629.
  5. Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, et al. French CCAFU guidelines-update 2020-2022: prostate cancer. J L'ass Franc D'urol Soc Franc D'urol. 2020;30:S136–251.
  6. AWMF. SW-leitlinie prostatakarzinom. 2021.
  7. AIOM. Linee Guida: Carcinoma Della Prostata. 2020.
  8. González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, et al. SEOM clinical guidelines for the treatment of advanced prostate cancer. Clin Translat Oncol. 2021;23(5):969–979.
  9. NICE. Metastatic prostate cancer guidelines. 2022.
  10. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501–5511.
  11. Vennemann M, Ruland V, Kruse JP, Harloff C, Trübel H, Gielen-Haertwig H. Future unmet medical need as a guiding principle for pharmaceutical R&D. Drug Disc Today. 2019;24(9):1924–1929.
  12. Boye M, Ribbands A, Leith A, Clayton E, Butcher J, Rybowski S. Real-world health-related quality of life and caregiver need in patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40:54.
  13. Nussbaum N, Dorff T, Abernethy A, Dolan C, Flanders S, Oestreicher N, et al. Health-related quality of life in metastatic castration-resistant prostate cancer: a critical literature review. Val Health.18(3):A211.
  14. Drudge-Coates L, Oh WK, Tombal B, Delacruz A, Tomlinson B, Ripley AV. Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey. Clin Genitour Canc. 2018;16(2):e411–419.
  15. Fallowfield L, Payne H, Jenkins V. Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nat Revs Oncol. 2016;13(10):643–650.
  16. Connor MJ, Genie MG, Burns D, Bass EJ, Gonzalez MC, Sarwar N, et al. A systematic review of patients’ values, preferences, and expectations for the treatment of metastatic prostate cancer. Euro Urol Open Sci. 2022;36:9–18.